CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 447 filers reported holding CRISPR THERAPEUTICS AG in Q2 2024. The put-call ratio across all filers is 1.06 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $4,591 | -20.8% | 85 | 0.0% | 0.00% | -50.0% |
Q1 2024 | $5,794 | +8.9% | 85 | 0.0% | 0.00% | +100.0% |
Q4 2023 | $5,321 | +37.9% | 85 | 0.0% | 0.00% | 0.0% |
Q3 2023 | $3,858 | -19.2% | 85 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $4,772 | +24.1% | 85 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $3,845 | +11.3% | 85 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $3,455 | +51.1% | 85 | +142.9% | 0.00% | 0.0% |
Q3 2022 | $2,287 | +7.5% | 35 | 0.0% | 0.00% | 0.0% |
Q2 2022 | $2,127 | -3.2% | 35 | 0.0% | 0.00% | 0.0% |
Q1 2022 | $2,197 | -17.2% | 35 | 0.0% | 0.00% | 0.0% |
Q4 2021 | $2,652 | – | 35 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |